AR and neoplasm: In vivo, it prevents tumor growth in AR-expressing xenograft models with limited toxicities [108].The most potent stereoisomer, EPI-002, was developed into a prodrug, EPI-506, which was the first AR NTD inhibitor tested in a Phase 1 study in men with CRPC.